{"organizations": [], "uuid": "688f9de6f7273e756c996a03b85cc625f67e38e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-reports-positi/brief-mabvax-therapeutics-reports-positive-safety-results-from-initial-cohort-of-mvt-1075-idUSASB0C7ZC", "country": "US", "domain_rank": 408, "title": "BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T14:39:00.000+02:00", "replies_count": 0, "uuid": "688f9de6f7273e756c996a03b85cc625f67e38e3"}, "author": "", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-reports-positi/brief-mabvax-therapeutics-reports-positive-safety-results-from-initial-cohort-of-mvt-1075-idUSASB0C7ZC", "ord_in_thread": 0, "title": "BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "mabvax therapeutics holdings inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 40 PM / in 9 minutes BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075 Reuters Staff 1 Min Read Feb 28 (Reuters) - Mabvax Therapeutics Holdings Inc : * MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS * MABVAX THERAPEUTICS HOLDINGS INC - ACHIEVED PRIMARY OBJECTIVES IN EARLY-STAGE CLINICAL TRIAL OF NOVEL RADIOIMMUNOTHERAPY PRODUCT MVT-1075 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-02-28T14:39:00.000+02:00", "crawled": "2018-02-28T15:04:25.014+02:00", "highlightTitle": ""}